Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN® in Respiratory Syncitial Virus (RSV)
(Thomson Reuters ONE) -
COPENHAGEN, Denmark - August 18, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) today announced the initiation of a Phase 1 clinical study of its MVA-
BN(®) RSV vaccine candidate against respiratory syncytial virus (RSV), the first
study to evaluate the vaccine candidate in humans.
The study, which is being conducted in USA, will evaluate the safety,
tolerability and immunogenicity of a recombinant MVA-BN-based RSV vaccine in 63
healthy adults, ages 18-65. Subjects will be enrolled into three groups to
receive different doses of MVA-BN RSV. One group will enroll subjects of 50-65
years of age who will receive a higher dose of MVA-BN RSV in order to evaluate
the immune responses in an elderly population, which is a key target for the
vaccine. Volunteers in each group will be randomized to receive two vaccinations
of MVA-BN RSV vaccine or placebo. More information on the trial can be found at
https://clinicaltrials.gov/ct2/show/NCT02419391.
Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: "The
addition of RSV to our clinical pipeline significantly expands the commercial
potential of our MVA-BN vaccine platform technology. RSV is an exciting
opportunity as it represents an area of high unmet medical need with no approved
vaccine available. Based on the broad protection seen in our preclinical data,
we believe that MVA-BN has the potential to address this opportunity. Once data
from this initial study are available, we plan to aggressively pursue the
development of this promising vaccine candidate in all potential risk
populations, including elderly and young children."
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
About RSV
RSV is the most common cause of lower respiratory tract infection in infants and
children worldwide, resulting in a high number of hospitalizations. By 2 years
of age virtually all infants have had an RSV infection. In addition, RSV causes
serious disease in elderly and immune compromised individuals, and results in a
comparable number of deaths in the elderly population as influenza. Currently,
there is no approved RSV vaccine available for any of these populations. It is
estimated that more than 64 million people are infected globally each year, thus
representing a blockbuster market opportunity for a safe and effective vaccine.
About MVA-BN(®) RSV
Bavarian Nordic's recombinant MVA-BN-based RSV vaccine candidate has been shown
to induce a balanced humoral and cellular immune response against both RSV
subtypes in preclinical models. Furthermore, the candidate has been shown to be
highly efficacious in preclinical models, including in studies sponsored by the
NIH.
About MVA-BN(®)
MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) is a proprietary and
patented vaccine platform technology of Bavarian Nordic, originally developed
through a successful public-private partnership with the U.S. Government. MVA-BN
is a robust and adaptable platform suitable for addressing a wide variety of
infectious diseases.
In addition to developing MVA-BN as a safer smallpox vaccine (approved in the EU
and Canada) essential to protecting the immune-compromised population, and
through a partnership with Janssen as an Ebola vaccine, Bavarian Nordic has
conducted more than a dozen preclinical and clinical studies of recombinant MVA-
BN-based vaccines. More than 7,600 individuals, nearly 1,000 of whom are
immunocompromised, have been vaccinated with MVA-BN-based vaccines, showing the
platform displays high immunogenicity and a favorable safety profile.
About Bavarian Nordic
Bavarian Nordic is a biopharmaceutical company focused on the development and
manufacturing of cancer immunotherapies and vaccines for infectious diseases.
Through a long-standing collaboration with the U.S. Government, Bavarian Nordic
has developed a portfolio of biological countermeasures, including the non-
replicating smallpox vaccine, IMVAMUNE(®), which is stockpiled for emergency use
by the U.S. and other governments. The vaccine is approved in the EU (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and its partner Janssen
are pioneering the development of an Ebola vaccine, which has been fast-tracked
by authorities in response to the current situation in West Africa.
Additionally, in collaboration with the National Cancer Institute, Bavarian
Nordic has developed a portfolio of active cancer immunotherapies based on its
versatile pox-virus based technologies, including PROSTVAC(®), which is
currently in Phase 3 clinical development for the treatment of advanced prostate
cancer. The company has partnered with Bristol-Myers Squibb for the potential
commercialization of PROSTVAC. For more information visit www.bavarian-
nordic.com or follow us on Twitter (at)bavariannordic.
Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
201522en:
http://hugin.info/100065/R/1946280/706129.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
[HUG#1946280]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Equitas Resources Corp. Announces $1,800,000 Non-Brokered Private PlacementDatum: 18.08.2015 - 16:04 Uhr
Sprache: Deutsch
News-ID 414507
Anzahl Zeichen: 6725
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN® in Respiratory Syncitial Virus (RSV)"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
